

Disclosure pursuant to article 26 sec 1 clause 2 WpHG (own shares) as per January 7, 2010

Disclosure of shareholding

Pursuant to article 26 sec 1 clause 2 WpHG BB BIOTECH AG, Schaffhausen, Switzerland, hereby reports that it increased its holding in own shares to more than 10% of the proportion of voting rights as of January 4, 2010 (a total of 1 832 159 shares / 10.05% of the proportion of voting rights).

Thereof, 7.58% of the proportion of voting rights (a total of 1 380 964 shares) are held through its wholly-owned subsidiary Biotech Target N.V., Curaçao, Netherlands Antilles.

For further information please contact:

Bellevue Asset Management AG, Seestrasse 16, CH-8700 Küsnacht/Zürich

Thomas Egger or Michael Hutter, Tel. +41 44 267 67 00

Company profile:

BB BIOTECH acquires holdings in companies in the biotechnology growth market and is currently one of the world's largest investors in the sector. BB BIOTECH is listed in Switzerland, in Germany and in Italy. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, BB BIOTECH relies on fundamental analysis by physicians and molecular biologists. The Board of Directors has many years of industrial and scientific experience.